Emerging roles of senolytics/senomorphics in HIV-related co-morbidities
Article
Kaur, G, Sohanur Rahman, M, Shaikh, S et al. (2024). Emerging roles of senolytics/senomorphics in HIV-related co-morbidities
. BIOCHEMICAL PHARMACOLOGY, 10.1016/j.bcp.2024.116179
Kaur, G, Sohanur Rahman, M, Shaikh, S et al. (2024). Emerging roles of senolytics/senomorphics in HIV-related co-morbidities
. BIOCHEMICAL PHARMACOLOGY, 10.1016/j.bcp.2024.116179
Human immunodeficiency virus (HIV) is known to cause cellular senescence and inflammation among infected individuals. While the traditional antiretroviral therapies (ART) have allowed the once fatal infection to be managed effectively, the quality of life of HIV patients on prolonged ART use is still inferior. Most of these individuals suffer from life-threatening comorbidities like chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension (PAH), and diabetes, to name a few. Interestingly, cellular senescence is known to play a critical role in the pathophysiology of these comorbidities as well. It is therefore important to understand the role of cellular senescence in the disease progression and co-morbidity development in HIV-infected individuals. In this respect, use of senolytic/senomorphic drugs as combination therapy with ART would be beneficial for HIV patients. This review provides a critical analysis of the current literature to determine the potential and efficacy of using senolytics/senotherapeutics in managing HIV infection, latency, and associated co-morbidities in humans. The various classes of senolytics have been studied in detail to focus on their potential to combat against HIV infections and associated pathologies with advancing age.
